Forest, Pierre Fabre release MDD drug Phase III trial results
The results of the trial demonstrated that levomilnacipran showed improvement in all dose groups, in comparison to placebo. Levomilnacipran, a sustained-release formulation, once-daily treatment was well tolerated in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.